Rakovina Therapeutics (TSXV:RKV) ROE % Adjusted to Book Value : -42.34% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics ROE % Adjusted to Book Value?

Rakovina Therapeutics's ROE % for the quarter that ended in Sep. 2024 was -118.12%. Rakovina Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was 2.79. Rakovina Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -42.34%.

Rakovina Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Rakovina Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics ROE % Adjusted to Book Value Chart

Rakovina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

-35.90

-18.34

-33.14

Rakovina Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial										-31.53	-44.43	-38.29	-39.89	-42.34

Competitive Comparison of Rakovina Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Rakovina Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rakovina Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's ROE % Adjusted to Book Value falls into.

Rakovina Therapeutics ROE % Adjusted to Book Value Calculation

Rakovina Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-54.02%	/	1.63
	=	-33.14%

Rakovina Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-118.12%	/	2.79
	=	-42.34%

Rakovina Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5

Website

https://www.rakovinatherapeutics.com

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.

Executives

Jeffrey Bacha	Senior Officer
Mads Daugaard	Senior Officer
Alfredo De Lucrezia	Director, Senior Officer
David Hyman	Senior Officer
John Michael Langlands	Senior Officer

Rakovina Therapeutics Headlines

No Headlines